Russian lawmaker comments on US decision to end military subsidies to UkraineRussian Politics & Diplomacy May 24, 16:30
Nine Russian missile regiments rearmed with advanced ICBM systemsMilitary & Defense May 24, 16:01
Perm session completes cycle of regional offsite events in run-up to SPIEF 2017Press Releases May 24, 15:38
Ka-52 helicopters to have advanced weapon targeting systemMilitary & Defense May 24, 15:09
Amsterdam Court may look into appeal against Scythian Gold ruling in fallSociety & Culture May 24, 15:04
Russian ground forces to be fully rearmed with Iskander-M ballistic missiles by late 2020Military & Defense May 24, 14:58
Russian security chief calls for cooperation on cyber threatsRussian Politics & Diplomacy May 24, 14:34
About half of Russian Navy warships to be armed with Kalibr cruise missiles by late 2020Military & Defense May 24, 14:31
Stalin’s grandson passes away at 75Society & Culture May 24, 14:26
GENEVA, October 3. /TASS/. The Court of Arbitration for Sport (CAS) is set to announce a decision on the appeal of Russian tennis star Maria Sharapova, submitted in summer against her two-year ban, on Tuesday, October 4, the court said in its statement on Monday.
"Decision in the case of Maria Sharapova v. International Tennis Federation to be released at 3.00 pm (Swiss time) on 4 October 2016," the statement said.
On June 9, Sharapova filed an appeal with the CAS in Switzerland’s Lausanne against her two-year suspension, which was imposed on June 8 by the International Tennis Federation’s (ITF) Tribunal over anti-doping violations.
Due to the imposed ban world’s former No. 1 Sharapova had to miss the 2016 Summer Olympic Games, held in August in Brazil’s Rio de Janeiro.
In early March, Sharapova announced that her doping tests revealed the presence of performance enhancing drug meldonium in the body system. Following the announcement, former World’s No. 1 was provisionally suspended from all tennis-related activities.
The drug meldonium (mildronate) was included in the list of preparations banned by WADA from January 1, 2016. The presence of the meldonium substance in the athlete’s blood during and between competitions is a violation of anti-doping rules. The substance belongs to S4 class on the WADA blacklist (hormones and metabolic modulators).
WADA announced on April 13 that the concentration of less than one microgram of meldonium in the body system of an athlete, whose doping tests were conducted before March 1, was acceptable.